On 17 June, 2016, all 28 European Union (EU) Health Ministers agreed on Council Conclusions to address the imbalances in the pharmaceutical systems in the EU and its Member States. In these Conclusions, the Ministers invited the European Commission to undertake a critical review of the impact of current intellectual property (IP) related incentives on biomedical innovation.
Evidence suggests that current levels of excessive IP rights and related monopoly protections do not contribute to genuine needs-driven medical innovation, and delay generic competition. Instead, this contributes to the development of ‘me too’ medicines, anti-competitive behaviours and high prices of new treatments that are not related to the costs of development.
Read the open letter to the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States” here: Open letter to EC-Council Conclusions – 13Sept